Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study.

Di WuPeng WangMeifang HanYongping ChenXinyue ChenQi XiaWeiming YanXiaoyang WanChuanlong ZhuQing XieJiaji JiangLai WeiDeming TanXiaoguang DouYanyan YuJinlin HouXiaoping LuoQin Ning

Published in: Hepatology international (2019)

For ETV-suppressed patients, particularly those with low baseline HBsAg levels, combination therapy with IFN and other immunomodulators may enhance HBsAg loss, while successful response correlates with partial restoration of NK cells and Tregs.

Keyphrases

combination therapy
end stage renal disease
hepatitis b virus
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
acute lymphoblastic leukemia
patient reported